Skip to content

A Prospective Randomized Controlled Trial of Paclitaxel/Carboplatin Neoadjuvant Chemotherapy Versus Radiothearpy in Patients with Locally Advanced Cervical Cancer/Stage IB2-IIA2 Squamous Cervical Carcinoma

A Prospective Randomized Controlled Trial of Paclitaxel/Carboplatin Neoadjuvant Chemotherapy Versus Radiothearpy in Patients with Locally Advanced Cervical Cancer/Stage IB2-IIA2 Squamous Cervical Carcinoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016715
Enrollment
Unknown
Registered
2018-06-19
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

NACT Group:TC NACT
concomitant chemo/radiotherapy:surgery/radiotherapy and direct chemo/radiotherapy

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) voluntary enrollment with informed consent signed; 2) primary cervical cancer confirmed by biopsy; 3) FIGO staged as IB2 to IIA2 by gynecological examination or imaging (the 2009 cervical cancer Figo staging standard); 4) aged under 70 years old; 5) abide by the program requirements with will and determination.

Exclusion criteria

Exclusion criteria: 1) patients who recieved previous cervical cancer treatment; 2) patients allergic to chemotherapy; 3) patients with severe hematological diseases or abnormalities; 4) patients with severe heart, kidney or liver dysfunction; 5) patients with active infection or other malignancies; 6) Inability to understand or follow research protocol due to cerebral or mental dysfunction; 7) Any cases in which the researchers think may increase the risk of the subjects or interfere the results of the test.

Design outcomes

Primary

MeasureTime frame
overall survival;progression-free survival;

Secondary

MeasureTime frame
Treatment response;

Countries

China

Contacts

Public ContactWang Zehua

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

zehuawang@163.net+86 13807177126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026